[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA201891447A1 - Кристаллическая форма 1,3-тиазол-5-илметил-[(2r,5r)-5-{[(2s)-2-[(метил-{[2-(пропан-2-ил)-1,3-тиазол-4-ил]метил}карбамоил)-мино]-4-(морфолин-4-ил)бутаноил-9-амино}-1,6-дифенилгексан-2-ил]карбамата или кобицистата - Google Patents

Кристаллическая форма 1,3-тиазол-5-илметил-[(2r,5r)-5-{[(2s)-2-[(метил-{[2-(пропан-2-ил)-1,3-тиазол-4-ил]метил}карбамоил)-мино]-4-(морфолин-4-ил)бутаноил-9-амино}-1,6-дифенилгексан-2-ил]карбамата или кобицистата

Info

Publication number
EA201891447A1
EA201891447A1 EA201891447A EA201891447A EA201891447A1 EA 201891447 A1 EA201891447 A1 EA 201891447A1 EA 201891447 A EA201891447 A EA 201891447A EA 201891447 A EA201891447 A EA 201891447A EA 201891447 A1 EA201891447 A1 EA 201891447A1
Authority
EA
Eurasian Patent Office
Prior art keywords
tiazol
butanoil
ilmetyl
diphenylhexan
methil
Prior art date
Application number
EA201891447A
Other languages
English (en)
Inventor
Чиажэнь Лай
Лок Хим Лоуренс Ю
Ричард Хун Чиу Ю
Эктор Новоа Де Армас
Original Assignee
Джилид Сайэнс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Джилид Сайэнс, Инк. filed Critical Джилид Сайэнс, Инк.
Publication of EA201891447A1 publication Critical patent/EA201891447A1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Molecular Biology (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Thiazole And Isothizaole Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

В настоящем изобретении предложена кристаллическая форма соединения формулы (Ia), способы получения кристаллической формы соединения формулы (Ia) и терапевтические способы применения кристаллической формы соединения формулы (Ia).
EA201891447A 2016-01-28 2017-01-24 Кристаллическая форма 1,3-тиазол-5-илметил-[(2r,5r)-5-{[(2s)-2-[(метил-{[2-(пропан-2-ил)-1,3-тиазол-4-ил]метил}карбамоил)-мино]-4-(морфолин-4-ил)бутаноил-9-амино}-1,6-дифенилгексан-2-ил]карбамата или кобицистата EA201891447A1 (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662288029P 2016-01-28 2016-01-28
PCT/US2017/014761 WO2017132158A1 (en) 2016-01-28 2017-01-24 Crystalline form of 1,3-thiazol-5-ylmethyl [(2r,5r)-5-{[(2s)-2-[(methyl{[2-(propan-2-yl)-1,3-thiazol-4-yl]methyl}carbamoyl)amino]-4-(morpholin-4-yl)butanoyl 9amino}-1,6-diphenylhexan-2-yl]carbamate or cobicistat

Publications (1)

Publication Number Publication Date
EA201891447A1 true EA201891447A1 (ru) 2019-03-29

Family

ID=57966186

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201891447A EA201891447A1 (ru) 2016-01-28 2017-01-24 Кристаллическая форма 1,3-тиазол-5-илметил-[(2r,5r)-5-{[(2s)-2-[(метил-{[2-(пропан-2-ил)-1,3-тиазол-4-ил]метил}карбамоил)-мино]-4-(морфолин-4-ил)бутаноил-9-амино}-1,6-дифенилгексан-2-ил]карбамата или кобицистата

Country Status (15)

Country Link
US (1) US20170217952A1 (ru)
EP (1) EP3408261A1 (ru)
JP (1) JP2019508393A (ru)
KR (1) KR20180101589A (ru)
CN (1) CN108834413A (ru)
AR (1) AR107441A1 (ru)
AU (2) AU2017211118B2 (ru)
BR (1) BR112018014643A2 (ru)
CA (1) CA3011930A1 (ru)
EA (1) EA201891447A1 (ru)
MA (1) MA46513A (ru)
MX (1) MX2018009056A (ru)
SG (1) SG11201806109RA (ru)
TW (1) TW201728582A (ru)
WO (1) WO2017132158A1 (ru)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2009242451C1 (en) 2008-05-02 2017-05-18 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
CN109384739B (zh) * 2017-08-14 2023-06-02 上海奥博生物医药股份有限公司 一种可比司他新晶型及其制备方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3696171T3 (pl) * 2006-07-07 2025-05-19 Gilead Sciences, Inc. Modulatory właściwości farmakokinetycznych środków leczniczych
AU2009242451C1 (en) * 2008-05-02 2017-05-18 Gilead Sciences, Inc. The use of solid carrier particles to improve the processability of a pharmaceutical agent
WO2012151165A1 (en) * 2011-05-02 2012-11-08 Gilead Sciences, Inc. Amorphous solid salts

Also Published As

Publication number Publication date
MX2018009056A (es) 2018-11-19
JP2019508393A (ja) 2019-03-28
BR112018014643A2 (pt) 2018-12-11
AR107441A1 (es) 2018-05-02
AU2017211118B2 (en) 2020-01-16
TW201728582A (zh) 2017-08-16
AU2017211118A1 (en) 2018-08-09
SG11201806109RA (en) 2018-08-30
CN108834413A (zh) 2018-11-16
CA3011930A1 (en) 2017-08-03
WO2017132158A1 (en) 2017-08-03
AU2019283825A1 (en) 2020-01-16
KR20180101589A (ko) 2018-09-12
US20170217952A1 (en) 2017-08-03
MA46513A (fr) 2019-08-21
EP3408261A1 (en) 2018-12-05

Similar Documents

Publication Publication Date Title
EA201991515A1 (ru) N-[4-фтор-5-[[(2s,4s)-2-метил-4-[(5-метил-1,2,4-оксадиазол-3-ил)метокси]-1-пиперидил]метил]тиазол-2-ил]ацетамид в качестве ингибитора oga
CY1121433T1 (el) Παραγωγα δικυκλικων ετεροκυκλυλιων ως αναστολεις irak4
CY1119383T1 (el) Αναστολεας ανθρωπινης ιστονικης μεθυλοτρανσφερασης εζη2 σε μορφη αλατος
EA201890594A1 (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
EA201790271A1 (ru) Ингибиторы гликозидазы
EA201592126A1 (ru) 6-мостиковые гетероарилдигидропиримидины для лечения и профилактики заражения вирусом гепатита b
PE20140302A1 (es) Inhibidores del virus de la hepatitis c
DK3220916T3 (da) Fremgangsmåde til behandling af cancer med n-((4,6-dimethyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-5-(ethyl(tetrahydro-2h-pyran-4-yl)amino)-4-methyl-4'-(morpholinomethyl)-[1,1'-biphenyl]-3-carboxamid
EA201591805A1 (ru) Оксабицикло [2.2.2] кислоты - модуляторы gpr120
EA201691150A1 (ru) Соединения изопропилтриазолопиридина
UY37517A (es) Métodos de síntesis de compuestos tiazoles sustituidos
PE20170148A1 (es) Compuestos de 1,3, 4-tiadiazol y uso de los mismos para el tratamiento del cancer
JOP20190050A1 (ar) مثبطات دوبامين-b-هيدروكسيلاز تخترق حاجز المخ الدموي
PE20190150A1 (es) 6-AMINOPIRIDIN-3-IL TIAZOLES COMO MODULADORES DE RORyT
EA201892235A1 (ru) Гранулированная композиция для перорального применения
EA201992360A1 (ru) Кристаллические формы (s)-афоксоланера
EA201791346A1 (ru) ТВЕРДЫЕ ФОРМЫ, ВКЛЮЧАЮЩИЕ (1E,4E)-2-АМИНО-N,N-ДИПРОПИЛ-8-(4-(ПИРРОЛИДИН-1-КАРБОНИЛ)ФЕНИЛ)-3H-БЕНЗО[b]-АЗЕПИН-4-КАРБОКСАМИД, ИХ КОМПОЗИЦИИ И ИХ ПРИМЕНЕНИЕ
MX386586B (es) Cristal de base libre de derivados benzofurano y método de preparación.
EA201891447A1 (ru) Кристаллическая форма 1,3-тиазол-5-илметил-[(2r,5r)-5-{[(2s)-2-[(метил-{[2-(пропан-2-ил)-1,3-тиазол-4-ил]метил}карбамоил)-мино]-4-(морфолин-4-ил)бутаноил-9-амино}-1,6-дифенилгексан-2-ил]карбамата или кобицистата
EA201791745A1 (ru) Производные тетрагидропиранилбензамида
WO2016132378A3 (en) Novel process for the preparation of 1,3-thiazol-5-ylmethyl [(2r,5r)-5-{[(2s)-2- [(methyl{[2-(propan-2-yl)- 1,3-thiazol-4-yl] methyl} carbamoyl) amino] -4-(morpholin-4-yl)butanoyl]amino}-1,6-diphenylhexan-2-yl] carbamate
EA202190045A1 (ru) Составы/композиции, содержащие ибрутиниб
FI3878444T3 (fi) (n-(2-((2-bentsyylifenyyli)amino)-2-oksoetyyli)-l-naftamidi) syöpälääkeaineena
SA522431923B1 (ar) عملية لتحضير دواء
MX391979B (es) Proceso de preparación de un inhibidor de inmunoproteasoma de péptido epoxicetona, y precursores del mismo.